Andrea Ruiz-Velasco
Overview
Explore the profile of Andrea Ruiz-Velasco including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
141
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al Sayed Z, Jouve C, Seguret M, Ruiz-Velasco A, Pereira C, Tregouet D, et al.
Stem Cell Reports
. 2024 Sep;
19(10):1417-1431.
PMID: 39303707
Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) offer great potential for drug screening and disease modeling. However, hiPSC-CMs remain immature compared to the adult cardiac cells. Cardiomyocytes isolated from adult...
2.
Chen X, Ruiz-Velasco A, Zou Z, Hille S, Ross C, Fonseka O, et al.
Diabetes
. 2024 Aug;
73(11):1805-1820.
PMID: 39137120
Article Highlights:
3.
Vermersch E, Neuvendel S, Jouve C, Ruiz-Velasco A, Pereira C, Seguret M, et al.
JCI Insight
. 2024 Jan;
9(3).
PMID: 38165745
The impairment of left ventricular (LV) diastolic function with an inadequate increase in myocardial relaxation velocity directly results in lower LV compliance, increased LV filling pressures, and heart failure symptoms....
4.
Ruiz-Velasco A, Raja R, Chen X, Ganenthiran H, Kaur N, Alatawi N, et al.
iScience
. 2023 Jun;
26(6):106970.
PMID: 37324527
Despite the development of clinical treatments, heart failure remains the leading cause of mortality. We observed that p21-activated kinase 3 (PAK3) was augmented in failing human and mouse hearts. Furthermore,...
5.
Kaur N, Gare S, Ruiz-Velasco A, Miller J, Abouleisa R, Ou Q, et al.
Heliyon
. 2023 May;
9(4):e14952.
PMID: 37123894
Diabetes is a metabolic disorder with an increased risk of developing heart failure. Inflammation and damaged vasculature are the cardinal features of diabetes-induced cardiac damage. Moreover, systemic metabolic stress triggers...
6.
Kaur N, Ruiz-Velasco A, Raja R, Howell G, Miller J, Abouleisa R, et al.
iScience
. 2022 Mar;
25(3):103973.
PMID: 35281739
Myocardial inflammation contributes to cardiomyopathy in diabetic patients through incompletely defined underlying mechanisms. In both human and time-course experimental samples, diabetic hearts exhibited abnormal ER, with a maladaptive shift over...
7.
Kaur N, Guan Y, Raja R, Ruiz-Velasco A, Liu W
Front Physiol
. 2021 Jul;
12:694864.
PMID: 34234695
The incidence of heart failure (HF) continues to increase rapidly in patients with diabetes. It is marked by myocardial remodeling, including fibrosis, hypertrophy, and cell death, leading to diastolic dysfunction...
8.
Kaur N, Raja R, Ruiz-Velasco A, Liu W
Front Cardiovasc Med
. 2020 Nov;
7:585309.
PMID: 33195472
Heart failure is a serious comorbidity and the most common cause of mortality in diabetes patients. Diabetic cardiomyopathy (DCM) features impaired cellular structure and function, culminating in heart failure; however,...
9.
Ruiz-Velasco A, Zi M, Hille S, Azam T, Kaur N, Jiang J, et al.
Elife
. 2020 Apr;
9.
PMID: 32223896
Myocardial insulin resistance contributes to heart failure in response to pathological stresses, therefore, a therapeutic strategy to maintain cardiac insulin pathways requires further investigation. We demonstrated that insulin receptor substrate...
10.
Nguyen B, Ruiz-Velasco A, Bui T, Collins L, Wang X, Liu W
Br J Pharmacol
. 2018 Jul;
176(22):4302-4318.
PMID: 29968316
Mitochondrial dysfunction is considered as a crucial contributory factor in cardiac pathology. This has highlighted the therapeutic potential of targeting mitochondria to prevent or treat cardiac disease. Mitochondrial dysfunction is...